Summary of Key Information:

Reporting Period (Quarter/Year): Quarter and Financial Year Ended March 31, 2026

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 of SEBI Listing Regulations

Audit Opinion:

Unmodified opinion issued by M/s. Natvarlal Vepari & Co., Chartered Accountants, Surat (FRN: 123626W) for both standalone and consolidated financial results.

Key Financial Highlights [Amount in INR million]

Standalone Results:

Revenue from Operations (FY26): 16,755.67 (vs. 8,958.99 in FY25)

Total Income (FY26): 16,955.30 (vs. 9,092.49 in FY25)

Net Profit (FY26): 1,613.96 (vs. 726.74 in FY25)

EPS (FY26): 14.32 (vs. 6.62 in FY25)

Other Equity (as at 31-03-2026): 31,211.04

Cash and Cash Equivalents (as at 31-03-2026): 561.74

Q4 FY26 Standalone Results:

Revenue from Operations: 3,705.79 (vs. 3,306.73 in Q4 FY25)

Net Profit: 423.84 (vs. 380.91 in Q4 FY25)

Consolidated Results:

Revenue from Operations (FY26): 23,654.55 (vs. 14,369.74 in FY25)

Total Income (FY26): 23,836.29 (vs. 14,484.51 in FY25)

Net Profit (FY26): 2,221.99 (vs. 1,599.72 in FY25)

Net Profit attributable to owners: 1,701.21 (vs. 933.49 in FY25)

EPS - Owners share (FY26): 15.09 (vs. 8.50 in FY25)

Other Equity (as at 31-03-2026): 31,879.90

Cash and Cash Equivalents (as at 31-03-2026): 3,780.69

Q4 FY26 Consolidated Results:

Revenue from Operations: 6,357.83 (vs. 5,001.58 in Q4 FY25)

Net Profit: 559.96 (vs. 629.28 in Q4 FY25)

Net Profit attributable to owners: 426.50 (vs. 445.67 in Q4 FY25)

Segment-wise Performance:

Based on the management approach defined in Ind AS 108, the Chief Operating Decision Maker (CODM) recognizes the company's business of custom synthesis and manufacturing of specialty chemicals as a sole business segment. Hence, segment-wise disclosure is not provided.

Corporate Actions:

  • Recommended a Final Dividend of ₹1.5 per equity share (15% of face value of ₹10 each) for the financial year 2025-26, subject to approval of members at the forthcoming 23rd Annual General Meeting.
  • Approved acquisition, directly or indirectly, of equity shares carrying voting rights of up to 74.20% of the total paid-up share capital and control of Bliss GVS Pharma Limited, a public limited company listed on BSE and NSE.
  • Approved raising funds by issuance of 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures (NCDs) with a face value of ₹1,00,000 each, aggregating to ₹160 crore (₹160,00,00,000), on a private placement basis.

Other Significant Information:

  • The consolidated results include the financials of multiple subsidiaries and one associate, including Jainam Intermediates Private Limited, Tanfac Industries Limited, ARIL Transmodal Logistic Private Limited, ARIL Fluorospeciality Private Limited, Anupam Japan GK, Anupam Europe AG, Anupam USA LLC, Anupam General Trading FZE, Doriath S.a.r.l., and its step-down subsidiaries (Monitchem Kansas S.a.r.l., Kansas HoldCo Inc., Kansas HoldCo I Inc., Jayhawk Fine Chemicals Corporation), and Tangent Science Private Limited (an associate).
  • Figures for previous periods have been re-grouped/rearranged/recasted wherever considered necessary.